Entries by Michelle Smith

,

Comparison of Cannabis-Based Medicinal Product Formulations for Fibromyalgia: A Cohort Study

This cohort study aims to assess the outcomes of fibromyalgia patients enrolled in the UK Medical Cannabis Registry prescribed a homogenous selection of cannabis-based medicinal products (CBMPs). A cohort study of fibromyalgia patients treated with oils (Adven®, Curaleaf International, UK), dried flower (Adven®, Curaleaf International, UK) or both CBMPs was performed. Primary outcomes were changes from baseline at 1, 3, 6 and 12 months in validated patient-reported outcome measures.

Prevalence and Effect of Cannabinoids in Pain Management for Hand Pathologies

Cannabinoids are a diverse group of compounds under investigation for various medical purposes, including analgesia. Given the evolving landscape of cannabinoid use, we aimed to analyze their prevalence and effect in pain management among urban orthopedic hand patients. An electronic survey was administered to 122 new patients presenting to the orthopedic hand clinic of a major urban academic hospital. Demographic data, numerical rating scale pain scores, cannabinoid usage, and other concomitant pain regimens were recorded.

The Effect of Orally Administered ∆9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) on Obesity Parameters in Mice

Prolonged cannabis users show a lower prevalence of obesity and associated comorbidities. In rodent models, ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD) from the plant Cannabis sativa L. have shown anti-obesity properties, suggesting a link between the endocannabinoid system (ECS) and obesity. However, the oral administration route has rarely been studied in this context. The aim of this study was to investigate the effect of prolonged oral administration of pure THC and CBD on obesity-related parameters and peripheral endocannabinoids.

The Effect of Oil-Based Cannabis Extracts on Metabolic Parameters and Microbiota Composition of Mice Fed a Standard and a High-Fat Diet

The prevalence of obesity and obesity-related pathologies is lower in frequent cannabis users compared to non-users. It is well established that the endocannabinoid system has an important role in the development of obesity. We recently demonstrated that prolonged oral consumption of purified ∆-9 Tetrahydrocannabinol (THC), but not of cannabidiol (CBD), ameliorates diet-induced obesity and improves obesity-related metabolic complications in a high-fat diet mouse model. However, the effect of commercially available medical cannabis oils that contain numerous additional active molecules has not been examined. We tested herein the effects of THC- and CBD-enriched medical cannabis oils on obesity parameters and the gut microbiota composition of C57BL/6 male mice fed with either a high-fat or standard diet.

Edible marijuana and cycle ergometer exercise

There is extensive public and scientific interest in the influence of cannabis and the psychoactive cannabinoid, delta-9-tetrahydrocannabinol (THC), on exercise performance. Unfortunately, recent, up-to-date studies are lacking. The aim of the current study was to address the hypothesis that ingestion of edible marijuana, prior to exercise, would have unfavorable effects on the physiological response to exercise and on exercise performance.

Cannabis use for exercise recovery in trained individuals: a survey study

Cannabis use, be it either cannabidiol (CBD) use and/or delta-9-tetrahydrocannabinol (THC) use, shows promise to enhance exercise recovery. The present study aimed to determine if individuals are using CBD and/or THC as a means of recovery from aerobic and/or resistance exercise, as well as additional modalities that might be used
to aid in recovery.

,

THC improves behavioural schizophrenia-like deficits that CBD fails to overcome: a comprehensive multilevel approach using the Poly I:C maternal immune activation

Prenatal infections and cannabis use during adolescence are well-recognized risk factors for schizophrenia. As inflammation and oxidative stress (OS) contribute to this disorder, anti-inflammatory drugs have been proposed as potential therapies. This study aimed to evaluate the association between delta-9-tetrahydrocannabinol (THC) and schizophrenia-like abnormalities in a maternal immune activation (MIA) model. Additionally, we assessed the preventive effect of cannabidiol (CBD), a non-psychotropic/anti-inflammatory cannabinoid.

,

Effects of cannabidiol on symptoms in people at clinical high risk for psychosis

Cannabidiol (CBD), a non‐intoxicating constituent of cannabis, has potential anxiolytic and antipsychotic properties 2 and a good safety profile. In two out of three clinical trials in patients with established psychosis, evidence of its antipsychotic efficacy has been reported 3 , 4 , 5 . However, there have not been trials of a period of treatment with CBD in CHR individuals. We assessed the clinical effects of a course of CBD treatment in people with a CHR state following a protocol approved by the National Research Ethics Service Committee London (Camberwell, St. Giles) (ISRCTN46322781).

COULD THE COMBINATION OF TWO NON- PSYCHOTROPIC CANNABINOIDS COUNTERACT HALOPERIDOL CATALEPSY? EFFECTIVENESS OF CANNABIDIOL ASSOCIATED WITH CANNABIGEROL

Cannabidiol (CBD) is a non-psychotomimetic compound from Cannabis sativa plant that produces antipsychotics effects in rodents and humans. CBD reduced catalepsy induced by typical antipsychotic haloperidol, a dopamine D2 receptor antagonist. CBD has been proposed to act as an atypical antipsychotic. Cannabigerol (CBG) is another non-psychoactive molecule from Cannabis sativa, a potential pharmaceutical for several neuropsychiatric conditions. In this study we investigated if CBG could have beneficial effects on motor related striatal disorders. We evaluated if CBG would prevent catalepsy induced by haloperidol (0.3mg/kg; s.c) and the c-Fos protein induction in the dorsal striatum.

Cannabis containing equivalent concentrations of delta‐9‐tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC‐dominant cannabis

Delta-9-tetrahydrocannabinol (THC), an active component of cannabis, can cause anxiety in some users during intoxication. Cannabidiol (CBD), another constituent of cannabis, has anxiolytic properties suggesting that cannabis products containing CBD in addition to THC may produce less anxiety than THC-only products. Findings to date around this issue have been inconclusive and could conceivably depend on moderating factors such as baseline anxiety levels in users.